FDA Panel: Autopsy Data Not Needed To Approve GE's Brain Imaging Agent
This article was originally published in The Gray Sheet
Executive Summary
Autopsy analysis is not always necessary as a comparator to support approval of new brain imaging agents, and certainly not in the case of GE Healthcare's DaTSCAN, an FDA advisory committee said Aug. 11